Strategic funding Imbria has recently secured a substantial Series B funding round totaling $57.5M with participation from new investors like Deep Track Capital and AXA IM Alts. This strong capital position supports accelerated clinical development, enabling BD teams to present a stable long-term partnership narrative to potential collaborators and investors.

Cardiometabolic focus The lead candidate ninerafaxstat targets energy metabolism in cardiovascular disorders, including nHCM, stable angina, and HFpEF. This broad yet focused clinical scope presents partner opportunities across cardiology centers, pharma collaborations, and contract research arrangements seeking metabolic modulation therapies.

Clinical expansion Advancing to Phase 2 across three indications demonstrates ongoing clinical progress and favorable development momentum. This trajectory can be leveraged to engage academic medical centers, KOLs, and contract development organizations as potential co-development or study sites.

Leadership momentum Recent leadership additions, including a new CEO and Chief Medical Officer, signal strategic execution and robust clinical leadership. This provides a credible entry point for high-level discussions with potential strategic partners and joint ventures seeking experienced collaborators.

Strategic partnerships Active collaborations and advocacy alignment, such as the HCMA partnership, indicate a commitment to patient-centric strategies and external validation. BD outreach can target patient advocacy groups, payer discussions, and research alliances to expand access, data generation, and market adoption pathways.